Company Description
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology.
The company’s LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides.
Its lead product candidate is MAT2203, an oral formulation of amphotericin B that is starting Phase 3 clinical trials for the treatment of aspergillosis and cryptococcosis, as well as prevention of invasive fungal infections in patients due to immunosuppressive therapy.
It offers MAT2501, an orally administered formulation of amikacin. The company has strategic collaborations with the National Institute of Allergy and Infectious Diseases; BioNTech SE to evaluate the combination of mRNA formats with the LNC platform; and Genentech Inc. to develop oral formulations.
The company was incorporated in 2013 and is based in Bedminster, New Jersey.
| Country | United States |
| Founded | 2013 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 3 |
| CEO | Jerome Jabbour |
Contact Details
Address: 1545 Route 206 South, Suite 302 Bedminster, New Jersey 07921 United States | |
| Phone | 908 484 8805 |
| Website | matinasbiopharma.com |
Stock Details
| Ticker Symbol | MTNB |
| Exchange | NYSEAMERICAN |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001582554 |
| CUSIP Number | 576810105 |
| ISIN Number | US5768101058 |
| Employer ID | 46-3011414 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Jerome D. Jabbour J.D. | Co-Founder, Chief Executive Officer and Chairman |
| Keith A. Kucinski CPA, M.B.A. | Chief Financial Officer |
| Frank Calamusa | Executive Director and Head of Manufacturing and Supply Chain |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 15, 2025 | 10-Q | Quarterly Report |
| May 12, 2025 | DEF 14A | Other definitive proxy statements |
| May 2, 2025 | PRE 14A | Other preliminary proxy statements |
| May 2, 2025 | 8-K | Current Report |
| Apr 29, 2025 | EFFECT | Notice of Effectiveness |
| Apr 29, 2025 | ARS | Filing |
| Apr 29, 2025 | 424B3 | Prospectus |
| Apr 22, 2025 | S-3 | Registration statement under Securities Act of 1933 |
| Apr 15, 2025 | 10-K | Annual Report |
| Apr 10, 2025 | SCHEDULE 13D/A | Filing |